Introduction
Cytochrome P450 2J2 (CYP2J2) has attracted particular attention for its ability to epoxidize arachidonic acid regio-selectively to 5,6-, 8,9-, 11,12-or 14,15- epoxyeicosatrienoic acids (EETs) (Roman, 2002) . These EETs have many biological functions including, but not limited to, angiogenesis, regulation of vasodilation, inhibition of cytokine-induced endothelial cell adhesion molecule expression, inhibition of vascular smooth muscle cell migration, protection of endothelial cells against hypoxia-reoxygenation injury, up-regulation of endothelial nitric oxide biosynthesis, and protection of doxorubicin-induced cardiotoxicity (Larsen et al., 2007; Spector and Norris, 2007; Yang et al., 2009; Zhang et al., 2009; Campbell and Fleming, 2010; Pfister et al., 2010) .
All these events are involved in cardiac electrophysiology and protect the heart from ischemic-reperfusion injury (Spiecker and Liao, 2006) . More specifically, the regioisomer 11,12-EET has been shown to be a potent activator of the ion channels sensitive to ATP, directly decrease the membrane action potential in rat myocytes (Lu et al., 2001 ) and enhance recovery of ventricular repolarization following ischemia reperfusion injury ). These investigations greatly increased interest in CYP2J2 with regard to its enzymology, localized expression, and the need for an in vitro model system suitable to study the enzyme's importance in maintaining cardiomyocyte homeostasis.
CYP2J2 is predominantly expressed in extrahepatic tissues, particularly in the heart, but also in skeletal muscle, placenta, small intestine, kidney, lung, pancreas, bladder and brain Zeldin et al., 1997; Bieche et al., 2007) . While a crystal structure has yet to be elucidated, molecular models suggest structural similarity DMD #53389 between CYP2J2 and CYP3A4 explaining why the two enzymes share a number of substrates of diverse therapeutic areas, such as the antihistamine drugs terfenadine, astemizole and ebastine (Matsumoto and Yamazoe, 2001; Hashizume et al., 2002; Matsumoto et al., 2002; Liu et al., 2006; Lafite et al., 2007) , anticancer drug tamoxifen, and drugs such as thioridazine or cyclosporine (Lee et al., 2012) . The combination of cardiac localization and involvement in the arachidonic acid metabolism makes CYP2J2 a particularly interesting target to mechanistically investigate drug-induced cardiotoxicity.
So far no studies demonstrated drug metabolism in the heart tissue. The inhibitory or inductive effect by such drugs on arachidonic acid metabolism could have profound down-stream consequences by reducing EETs and their protective properties. However, a human heart model remains elusive and testing relies on animal models, especially dog, cell systems or recombinant enzymes. Much of CYP2J2's activity has been assessed in such models as E.coli expressed or Baculovirus-infected insect cell expressed enzyme (Supersomes ®) (Lafite et al., 2007) , human liver microsomes (Lee et al., 2012) or in humanized animal models that over express the enzyme in cardiac tissue (Seubert et al., 2004; Deng et al., 2011) .
In this study, we evaluate commercially available primary human cardiomyocytes for expression and activity of CYP2J2. We first cloned and expressed CYP2J2 and measured its activity. Second, we evaluated the expression of a range of important CYPs in addition to CYP2J2 in human cardimyocytes by mRNA content compared to levels of CYP expression in human ventricular tissue. Third, we assessed the metabolic activity of CYP2J2 in the cardiomyocytes towards the probe substrates and characterized the kinetic DMD #53389 the pCW2J2 expression construct (Barnes et al., 1991) . The constructs were generated by PCR amplification with the primers 
Protein Expression
Protein expression was performed as previously described (Cheesman et al., 2003; Kaspera et al., 2011) and harvested cells were resuspended in storage buffer and stored in -80 °C until purification:
Protein Purification
Frozen pellets were thawed on ice and resuspended in 100 mM potassium phosphate (pH 7.4) containing 20% glycerol and protease inhibitors. Purification was conducted following established procedures (Kaspera et al., 2011) .
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Measurement of P450 Concentration
CO-difference spectra were obtained to determine the concentration of purified CYP2J2
according to the method of Omura and Sato (Omura and Sato, 1964 Recombinant CYP2J2 was reconstituted with reductase and lipid according to previously established protocols (Kaspera et al., 2011) . Briefly, the mixture used was as follows; 1 pmol/mL recombinant CYP2J2 was mixed with 2pmol/mL rat cytochrome P450 reductase, 1pmol/mL Cytochrome b 5 , buffer containing 100 mM potassium phosphate (pH 7.4), and 50 μ M DLPC on ice for 40 min with intermittent mixing. Incubations were performed in a total volume of 200 μ L buffer containing 100 mM potassium phosphate (pH 7.4), 1 pmol P450/mL reconstituted CYP2J2 and varying terfenadine concentrations (0, 0.05, 0.075, 0.1, 0.2, 0.5, 1, 2, 5, 10, and 20 μ M in methanol). The final methanol concentration in the incubations was 1% and was previously determined to not affect enzyme activity. The reactions were initiated by addition of 1mM NADPH following a 5 minute preincubation at 37 °C (shaking at 70 strokes per minute CYP2J2 mRNA present in the cells relative to the GusB mRNA levels. In the case of the CYP enzyme screen, the mRNA levels were first determined in relation to the housekeeping gene using the Δ C T method and then the levels of each CYP mRNA were compared to the levels of CYP2J2 mRNA levels using the Δ Δ C T calculation and relative CYP mRNA levels were reported using the 2 -ΔΔCT calculation.
CYP protein content determination
To determine protein content, approximately one million cells were pelleted and The protein content was determined using a standard curve containing the following concentrations of synthesized unlabeled peptide (nM): 0, 0.5, 1, 2.5, 5, 10, 25, 50, 100, 500. The internal standard concentration was the same as above (50 nM).
Kinetic parameters of CYP2J2-mediated Metabolism in Human Cardiomyocytes
Experiments to determine K m and V max of terfenadine and astemizole hydroxylation by In order to rule out potential involvement by CYP3A4 or CYP2C8, we also conducted activity experiments with probe substrates for CYP3A4 and CYP2C8. The incubations were carried out as outlined for K m and V max determination CYP2J2 above but using 
Induction of CYP2J2 mRNA in Human Cardiomyocytes
Cells that had been plated in 6-well plates and allowed to attach overnight were treated 
Rosiglitazone inhibition of CYP2J2 activity
The ability of rosiglitazone to inhibit CYP2J2 biotransformation of terfenadine was determined by co-incubating BD Gentest CYP2J2 supersomes (1 pmol/mL), terfenadine 
Data analysis
Apparent Michaelis-Menten constants K m and V max were derived after nonlinear regression analysis of the kinetic data using a Michaelis-Menten model (Prism 5 windows version 5.02, GraphPad Software, Inc., La Jolla, CA). Kinetic data is reported as the mean ± S.D. of triplicates in cells and as the mean ± standard error of duplicates when using recombinant enzyme (computer generated).
Results

Expression and Kinetics of Recombinant E. coli Expressed CYP2J2
SDS-PAGE analysis showed a band at 57kDa consistent with full length CYP2J2 protein, and a CO-difference spectrum showed active P450 and no inactive P420 present (data not shown). Expressed CYP2J2 protein was assayed for metabolic activity using terfenadine which displayed Michaelis-Menten kinetics with a K m of 1.55 µM ( figure 1, table 1 ).
Enzyme activity was expressed as rate of alcohol metabolite formed, using the peak height as a quantitative comparison to internal standard.
Cytochrome P450 mRNA Screen
CYP2J2 was the major isozyme expressed among the CYPs that were screened in human cardiomyocytes (figure 2). CYP2D6, and CYP2E1 were also detected at levels approximately twenty fold below that of CYP2J2. In human heart tissue, CYP2J2 had also the greatest expression level. Several other CYP isozymes complemented CYP2J2 expression in human heart tissue, including CYP2C8, CYP2D6, CYP2E1, CYP2V1, CYP3A4, CYP4A11, CYP4B1, and CYP4F12, but expression levels were at least fifty fold lower than that of CYP2J2.
CYP2J2 Protein Content Determination
Using mass spectrometry, the average expression of CYP2J2 in cardiomyocytes, is 2.96 pmol per 1 million cells.
Kinetic Parameters of Drug Metabolism in Human Cardiomyocytes
Drug metabolic activity was measured in the cells using both terfenadine and astemizole as probe drugs. Both drugs were oxidized and exhibited Michaelis-Menten kinetics with a figure 3B, table 1 ). In contrast to astemizole, terfinadine was toxic to the cells at at higher concentrations.
Inhibition of CYP2J2 in Human Cardiomyocytes
Inhibition was assessed at two concentrations of substrate ( but the degree to which they inhibited was not as pronounced as it was at substrate concentration of 0.2 uM (figure 4B).
Hormone Effects on Gene Expression
CYP2J2 induction by the sex hormones β -estradiol and testosterone demonstrated that β -estradiol increased mRNA transcript levels in a concentration dependent manner, while testosterone decreased transcription of CYP2J2 (figure 5). However, changes in the levels of transcription were not statistically different from control untreated cells. When examining CYP2J2 mRNA expression, many of the compounds screened did not result in an increased gene expression ( Figure 6A ). An increase in CYP2J2 mRNA was observed when the cells were treated with rosiglitazone (>50 % increase), BHA (50 % increase), and BHT (40 % increase). Slight decreases in mRNA content were observed in the cells when treated with dexamethasone, clotrimazole, and ritonavir.
Induction of CYP2J2 in Human Cardiomyocytes
The greatest increase in enzyme activity occurred when the cells were treated with carbamazepine (30% increase), though this was not significant. Ritonavir treatment showed >95% decrease in terfenadine hydroxylation by CYP2J2. Phenytoin, phenobarbital, rosiglitazone, omeprazol and clotrimazol also reduced CYP2J2 activity ( Figure 6B ). Other compounds did not appreciably affect the enzyme's ability to oxidize terfenadine.
Post induction, there was no appreciable decrease in protein levels in cells treated with rosiglitazone, ritonavir or BHT indicating that these agents do not affect protein stability.
(Supplemental Figure 1) Intracellular levels of terfenadine post induction were also measured. In cells treated with ritonavir and rosiglitazone, terfenadine levels were decreased by 50% compared to untreated cells, but was unchanged relative to control when treated with BHT. 
Discussion
Here a primary cardiac cell line was examined for its potential use to screen for cardiac metabolism related liabilities. These ventricular cells are derived from adult humans, which is important considering the interspecies differences in CYP2J activity previously reported (Ma et al., 2004; Yamasaki et al., 2004; Aiba et al., 2006; Elshenawy et al., 2013) . Further, many of the drug induced cardiotoxicity can be attributed to ventricular tissue. The P450 mRNA expression profile was similar to human cardiac ventricular tissue with CYP2J2 by far the dominant isoform. The ability of the cells to metabolize CYP2J2 substrates astemizole and terfenadine was also established. Various compounds most notably danazol and ketoconazole readily inhibited CYP2J2 activity. However, CYP2J2 mRNA were mostly unchanged in the presence of potential inducers.
Others have shown the dominant presence of CYP2J2 in cardiac tissue, using immunoblotting or quantitative real-time PCR (Wu et al., 1996; Michaud et al., 2010) .
The expression of various CYP isozymes in the heart, including CYP1A1, CYP2B6, CYP2C8, CYP2C19, CYP2J2, and CYP2E1 are also reported (Wu et al., 1996; Thum and Borlak, 2000; Michaud et al., 2010) . In the cardiac cell line, the expression of CYP2J2
agrees well with previously published data but the cellular expression levels of the CYP2C sub-family were below limits of detection. DeLozier et al detected CYP2C in cardiac tissue samples, which were prepared from whole heart tissue (Delozier et al., 2007) . The cells investigated here are derived from ventricular tissue and do not contain endothelial cells. It is possible that the CYP2C expression in the heart tissue is localized to endothelial cells and not cardiomyocytes. Km values for terfenadine hydroxylation were comparable in the cells and E. coli expressed system but were 10 fold higher than supersomes(1.5µM vs. 0.2 µM respectively). The similarity of terfenadine hydroxylation seen in cells and E.coli models (with deviations at high substrate concentration due to inhibition or cell toxicity) is a promising indication that these cells present a well suited model of drug metabolism in the heart. Similar protein concentration of 0.2-0.3 pmol of CYP2J2 were used for Km experiments in the cardiomyocytes and E. coli expressed. It should be noted that the E.coli-expressed enzyme CYP2J2 has a truncation at the N-terminus and a 6x His-tag at the C-terminus for purification purposes. It is unclear at this time whether these modifications alter the enzyme's activity to any significant degree. Another potential source of variability is the difference in the ratio between CYP2J2 and its redox partners, cytochrome P450 reductase (CPR) and cytochrome b5. Supersome systems by BD Gentest have variable ratios, while reconstituted systems maintain a 1:2:1 ratio of CYP:CPR:b5. Further, commercial supersomes contain human CPR, while reconstituted systems use rat CPR. In addition, the role of specific and non-specific binding of terfenadine to the cells in altering the Km value cannot be determined at this time.
To test the inhibition of terfenadine hydroxylation in the heart, potential inhibitors with a documented history of cardio toxicity were selected. Danazol was included because it is a specific inhibitor of CYP2J2 and causes congestive heart failure with prolonged use (Lee et al., 2012) . Two inhibitor concentrations were used ( Using substrate concentrations at sub K m levels would reflect the competitive inhibition more clearly operating in the linear range of substrate turnover. As expected, danazol greatly inhibited CYP2J2 this cell system, reinforcing CYP2J2's role in metabolism of terfenadine in the heart. The inhibition of CYP2J2 activity by drugs such as ketoconazole and ritonavir were also expected, particularly because these drugs are reported to inhibit CYP2J2 in supersomes, and also known to inhibit CYP3A4 (Lee et al., 2012) . Interestingly, sertindole, tacrolimus and levomethadyl, at lower concentrations increased CYP2J2 activity, possibly due to allosterism or other cell distribution phenomena not accounted for in this study (such as transport).
Induction of CYP2J2 was evaluated at both the transcriptional and protein activity levels.
A 48 hour induction period was chosen after preliminary studies indicated that significant cell death occurred at 72 hours. In 2010 Lee and Murray reported butylated hydroxyanisole (BHA) as a CYP2J2 inducer in HepG2 cells .
Further work by Ma et al has shown that the mouse ortholog, CYP2J5, is regulated by sex hormones in murine kidneys (Ma et al., 2004) . The results of this study, however, show that in cardiomyocyte, neither BHA nor the sex hormone cell media frequently during their induction (at 6h, 12h, 18h, 24h, and 48h) whereas BHA was replenished at 24h in this study.
This inability to induce CYP2J2 in cardiomyocytes indicates an important endogenous function with expression and activity tightly regulated in order to preserve or protect the cell. This is supported by the G-50T mutation, the only other notable CYP2J2-allele reported across ethnic groups. Carriers of this allele have decreased expression of the CYP2J2 gene and have been shown to have increased risk of adverse cardiac effects (Spiecker et al., 2004; Marciante et al., 2008; Zhang et al., 2008) . A delicate balance of expression levels might be needed and interference with physiological pathways could have detrimental effects.
Other compounds tested for the ability to induce CYP2J2 transcription and CYP2J2 activity are classical CYP inducers, which bind to the pregnane X receptor (PXR) (Fahmi et al., 2012) . Of note, rosiglitazone simultaneously induced transcription of mRNA but also inhibited terfenadine hydroxylation. Rosiglitazone is a known mild PXR inducer (Sinz et al., 2006) , however, if rosiglitazone was operating through the PXR receptor, then rifampin should have induced mRNA as well. Rosiglitazone ispotentially binding and inducing CYP2J2 through PPAR (peroxisome proliferator-activated) receptor which also induces mRNA of CYP2B and CYP4 enzymes (Rogue et al., 2010) . . Also, while our goal was to find potential inducers of CYP2J2 transcription and CYP2J2
protein, it appears that some drugs reduced terfenadine hydroxylation such as ritonavir and rosiglitazone. The decrease in terfenadine hydroxylation could potentially be due to the drug inhibiting the transporter responsible for uptake of terfenadine into the cell. Our data shows that the amount of terfenadine remaining in the cell were at least 50% lower than control samples (Supplemental Figure 2) . This indicates that terfenadine is perhaps unable to enter the cell following the induction treatment due to the inhibition of transporters by xenobiotics. Currently, not much is known about which drug transporters are expressed in these cardiomyocytes and further studies are needed. Protein degradation instigated by either ritonavir or rosiglitazone is another possible explanation. However, our studies indicate no significant decrease in the amount of CYP2J2 protein in these cells following drug treatment.
Another potential source of cardiomyocytes being investigated for drug screening are derived from human pluripotent stem cells (hPSCs) (Dick et al., 2010; Zeevi-Levin et al., 2012) . Many of these studies, however, focus on the electrophysiological aspects of the cardiomyocyte, which are unfortunately absent in the cells presented in this study.
Despite this, we have shown that these primary cells still maintain the ability to express drug metabolizing enzymes in agreement with published data in heart tissue. While the heart is not primarily involved in drug-metabolism, the presence of these CYPs, particularly CYP2J2, suggests the potential for drug-drug interactions in the heart. To our knowledge, there are no studies in hPSC-derived cardiomyocytes (hPSC-CMs) that characterize their expression of drug-metabolizing enzymes. Lastly, hPSC-CM have current limitations such as large scale use, incomplete differentiation and immaturity (Mordwinkin et al., 2013) , making these primary cells a promising alternative.
In conclusion, this work provides an important step towards identifying a model that could investigate metabolism related drug adverse effects in the heart during preclinical investigations. The cardiomyocyte cell line is of human derived ventricular cells, but it is important to note that these primary lines exhibit potential drawbacks (e.g. heterogeneity
